3-methylamino-1-(2-thienyl)-1-propanone, production and use thereof
Granted 21 Aug 2007 · 2 office actions
Current assignee: BASF Aktiengesellschaft · originally BASF SE
Law firm: Law firm · Log in to unlock
Attorney: Attorney · Log in to unlock
Inventors: Rainer Stürmer · Examiner: Rebecca Anderson · AU 1626 · TC 1600
Life of the application
10 dated eventsAbstract
The present invention relates to the preparation of 3-methylamino-1-(2-thienyl)-1-propanone and its use for preparing the pharmaceutical (+)-(S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine oxalate—(trade name Duloxetine®).
Description
2 parts›RELATED APPLICATIONS · 1 of 2
This application is a national stage application (under 35 U.S.C. 371) of PCT/EP2004/000237 filed Jan. 15, 2004 which claims benefit to German application 103 02 595.2 filed Jan. 22, 2003.
The present invention relates to the preparation and use of 3-methylamino-1-(2-thienyl)-1-propanone.
The amino alcohol 1 ( FIG. 1 ) [(1S)-3-methylamino-1-(2-thienyl)propan-1-ol] is a sought-after intermediate in the preparation of a pharmaceutical ((+)-(S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine oxalate—trade name Duloxetine®). The method which has been used thus far for preparing this intermediate is elaborate and requires expensive and labile reagents. Furthermore, a technically elaborate chromatography is required for preparing a pure compound. See, for example, EP 273658 A1; Liu et.al., Chirality 2000, 12 (1), 26-29; Wheeler et. al, J. Labelled Comp. Radiopharm. 1995, 36(3), 213-23; U.S. Pat. No. 5,362,886, EP 457559, Deeter et al , Tet. Lett. 1990, 31(49), 7101-4; EP 0650965; L. A. Sorbera, R. M. Castaner, J. Castaner, Drugs of the Future 2000, 25(9): 907-916.
The object therefore was to make available simpler and more economical processes for preparing Duloxetine®.
The present invention describes novel and economical processes for obtaining the isomerically pure compound 1. As an intermediate which they share in common, the processes according to the invention use the novel ketone 5 ( FIG. 1 ) [3-methylamino-1-(2-thienyl)-1-propanone], from which the amino alcohol 1 can be obtained by means of enantioselective reduction. The subsequent reaction of the aminoalcohol 1 to give Duloxetine® is well known to the skilled person and can be carried out in analogy with the process described in EP 0457559 A2 (reaction with 1-fluoronaphthalene).
The invention relates to 3-methylamino-1-(2-thienyl)-1-propanone ( FIG. 1 , compound 5) and its acid addition salts. The acid addition salts of compound 5 are products of the reaction of compound 5 with inorganic or organic acids. Acids which are particularly suitable for this purpose are hydrochloric acid, sulfuric acid, phosphoric acid, oxalic acid, fumaric acid, maleic acid and acetic acid.
The starting compound for preparing the ketone 5 or the amino alcohol 1 can be thiophene or 2-acetylthiophene. FIG. 1 depicts three routes for preparing the ketone 5 (routes 1 to 3), which routes are described below:
Route 1
Compound 4 is obtained by way of a classical Mannich reaction starting with acetylthiophene, formaldehyde and dimethylamine (EP 0457559 A2 Example 1). The monomethylamino ketone 5 is obtained by means of a retromichael/Michael reaction, by reacting 4 with an excess of methylamine.
Route 2
Compound 6 is obtained by means of a classical Mannich reaction starting with acetylthiophene, formaldehyde and methylamine (Blicke; Burckhalter; JACSAT; J. Amer. Chem. Soc.; 64; 1942; 451, 453). The monomethylamino ketone 5 is obtained by means of a retromichael/Michael reaction, by reacting 6 with an excess of methylamine.
Route 3
The compound 7 is obtained by means of a classical Friedel-crafts acylation of thiophene 8 with 3-chloropropionyl chloride (described in El-Khagawa, Ahmed M.; El-Zohry, Maher F.; Ismail, Mohamed T.; PREEDF; Phosphorus Sulfur; EN; 33; 1987; 25-32). The monomethylamino ketone 5 is obtained by reaction with methylamine.
The invention also relates to the use of 3-methylamino-1-(2-thienyl)-1-propanone or its acid addition salts for preparing N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine, or its acid addition salts, in racemic or enantiomerically pure form. Particular preference is given to the use for preparing (+)-(S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine oxalate (Duloxetin®).
The invention also relates to a process for preparing N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine, or its acid addition salts, in racemic form or, preferably, in enantiomerically pure form, with 3-methylamino-1-(2-thienyl)-1-propanone or its acid addition salts being prepared as intermediate in a first step with this intermediate then being reduced to the corresponding alcohol.
The reduction can be carried out either under racemizing conditions or enantioselectively. Preference is given to an enantioselective reduction, in particular to such a reduction which yields the (S)-enantiomer 1 as the product.
This can be carried out either chemically, using classical enantioselective hydrogenation methods,. such as using NaBH 4 or LiAlH 4 , which are provided with chiral ligands for the purpose of achieving enantioselectivity, or using transition metal-containing hydrogenation catalysts or using enzymic reductions, for example using microbial, in particular bacterial or fungal, dehydrogenases.
Experimental:
Route 1:
5 g of dimethylamino ketone 4 are initially introduced as the hydrochloride in 25 ml of ethanol after which 20 eq. of methylamine (40% in water) are added dropwise and the mixture is stirred at 60-70° C. for 6 h. After the reaction has come to an end, part of the ethanol is removed and the product 5 is obtained as a white crystalline solid (yield, 3.45 g as the hydrochloride).
Route 2:
5 g of diketone 6 are initially introduced, as the hydrochloride, in 25 ml of ethanol after which 20 eq. of methylamine (40% in water) are added dropwise and the mixture is stirred at 70-80° C. for 6 h. After the reaction has come to an end, part of the ethanol is removed and the product 5 is obtained as a white crystalline solid (yield, 3.87 g as the hydrochloride).
Route 3:
5 g of chloroketone 7 are initially introduced in 25 ml of THF after which 20 eq. of methylamine (40% in water) are added dropwise and the mixture is stirred at 30-40° C. for 6 h. After the reaction has come to an end, most of the THF is removed and the product 5 is isolated as a white crystalline solid (yield, 4.10 g as the hydrochloride).
In routes 1-3, aqueous methylamine can also be replaced with gaseous or liquefied methylamine.
Spectroscopic data for the monomethylamino ketone 5 as the hydrochloride:
›RELATED APPLICATIONS · 2 of 2
13 C NMR (D 2 O, 125 MHz) spin-echo multiplicities in brackets: δ (ppm)=188.5 (s), 140.4 (s), 139.2 (d), 137.8 (d), 131.9 (d), 46.9 (t), 37.3 (t), 36.0 (q) 1 H NMR (D 2 O, 500 MHz): δ (ppm)=8.00 (m, 1H), 7.95 (m, 1H), 7.25 (m, 1H), 3.40 (m,2H), 2.75 (m, 2H), 2.62 (s, 3H)
Reduction of compound 5 to give compound 1 ( FIG. 1 )
NaBH4 (racemic):
5 g of methylamino ketone 5 were initially introduced in 20 ml of ethanol after which 0.8 eq. of NaBH4 was added in portions at 20° C. After the mixture had been stirred for 6 h, it was subjected to aqueous workup. The racemic monomethylaminoalcohol 1 was obtained as a pale yellow solid (yield: 3.9 g)
1H NMR (500 MHz, CDCl3) δ(ppm)=2.1 (m, 2H), 2.5 (s, 3H), 2.9 (m, 2H), 4.5 (br s, 2H), 5.25 (m, 1H), 6.94 (m, 1H), 7.00 (m, 1H), 7.22 (m,1H) 13C NMR (125 MHz, CDCl3) δ (ppm)=35.4, 36.3, 49.7, 71.4, 122.5, 123.8, 126.6, 149.3
LiAlH4 (chirally modified) carried out as in EP 0457559 A2, example 1B (enantioselectively).
The yield of 1 was 74%, with an enantiomeric purity of 72% ee.
Claims as granted
1 claimLog in to read the claims of this application.
Log in to unlockClassifications
4 codes- C07D333/20
- C07D333/16
Claim changes
SoonSee which claims were amended, added or cancelled during examination, with every added and removed word marked.
The published claims of this application are not paired with the granted ones in what we hold.
File wrapper
See the full prosecution history — every USPTO and applicant action on this file, in order.
Log in to unlockDocuments
Log in to open the documents of this file: the application as filed, every office action and response, the notice of allowance.
Log in to unlockChain of title
See the full assignment history — every owner this patent has passed through, with recordation dates and reel/frame numbers.
Log in to unlock